Literature DB >> 22151035

In vitro activity of antibiotic combinations against multidrug-resistant strains of Acinetobacter baumannii and the effects of their antibiotic resistance determinants.

Yoko Miyasaki1, Margie A Morgan, Raymond C Chan, W Stephen Nichols, Kristine M Hujer, Robert A Bonomo, A Rekha Murthy.   

Abstract

Various combinations of antibiotics are reported to show synergy in treating nosocomial infections with multidrug-resistant (MDR) Acinetobacter baumannii (A. baumannii). Here, we studied hospital-acquired outbreak strains of MDR A. baumannii to evaluate optimal combinations of antibiotics. One hundred and twenty-one strains were grouped into one major and one minor clonal group based on repetitive PCR amplification. Twenty representative strains were tested for antibiotic synergy using Etest(®). Five strains were further analyzed by analytical isoelectric focusing and PCR to identify β-lactamase genes or other antibiotic resistance determinants. Our investigation showed that the outbreak strains of MDR A. baumannii belonged to two dominant clones. A combination of colistin and doxycycline showed the best result, being additive or synergistic against 70% of tested strains. Antibiotic additivity was observed more frequently than synergy. Strains possessing the same clonality did not necessarily demonstrate the same response to antibiotic combinations in vitro. We conclude that the effect of antibiotic combinations on our outbreak strains of MDR A. baumannii seemed strain-specific. The bacterial response to antibiotic combinations is probably a result of complex interactions between multiple concomitant antibiotic resistance determinants in each strain.
© 2011 Federation of European Microbiological Societies. Published by Blackwell Publishing Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22151035      PMCID: PMC3280091          DOI: 10.1111/j.1574-6968.2011.02480.x

Source DB:  PubMed          Journal:  FEMS Microbiol Lett        ISSN: 0378-1097            Impact factor:   2.742


  21 in total

1.  Rapid method of extraction and analysis of extended-spectrum beta-lactamases from clinical strains of Klebsiella pneumoniae.

Authors:  D L Paterson; L B Rice; R A Bonomo
Journal:  Clin Microbiol Infect       Date:  2001-12       Impact factor: 8.067

2.  Evaluation of antibiotic synergy against Acinetobacter baumannii: a comparison with Etest, time-kill, and checkerboard methods.

Authors:  C R Bonapace; R L White; L V Friedrich; J A Bosso
Journal:  Diagn Microbiol Infect Dis       Date:  2000-09       Impact factor: 2.803

Review 3.  Global challenge of multidrug-resistant Acinetobacter baumannii.

Authors:  Federico Perez; Andrea M Hujer; Kristine M Hujer; Brooke K Decker; Philip N Rather; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2007-07-23       Impact factor: 5.191

4.  Comparative activities of colistin, rifampicin, imipenem and sulbactam/ampicillin alone or in combination against epidemic multidrug-resistant Acinetobacter baumannii isolates producing OXA-58 carbapenemases.

Authors:  Marie-Francoise Tripodi; Emanuele Durante-Mangoni; Rosaria Fortunato; Riccardo Utili; Raffaele Zarrilli
Journal:  Int J Antimicrob Agents       Date:  2007-09-11       Impact factor: 5.283

Review 5.  Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America.

Authors:  Helen W Boucher; George H Talbot; John S Bradley; John E Edwards; David Gilbert; Louis B Rice; Michael Scheld; Brad Spellberg; John Bartlett
Journal:  Clin Infect Dis       Date:  2009-01-01       Impact factor: 9.079

6.  Comparison of three different in vitro methods of detecting synergy: time-kill, checkerboard, and E test.

Authors:  R L White; D S Burgess; M Manduru; J A Bosso
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191

7.  In-vitro activity of the combination of colistin and rifampicin against multidrug-resistant strains of Acinetobacter baumannii.

Authors:  G M Hogg; J G Barr; C H Webb
Journal:  J Antimicrob Chemother       Date:  1998-04       Impact factor: 5.790

8.  Interactions of colistin and rifampin on multidrug-resistant Acinetobacter baumannii.

Authors:  E J Giamarellos-Bourboulis; E Xirouchaki; H Giamarellou
Journal:  Diagn Microbiol Infect Dis       Date:  2001-07       Impact factor: 2.803

9.  Efficacy of monotherapy and combined antibiotic therapy for carbapenem-resistant Acinetobacter baumannii pneumonia in an immunosuppressed mouse model.

Authors:  Joon Young Song; Hee Jin Cheong; Jacob Lee; Ah Kyeong Sung; Woo Joo Kim
Journal:  Int J Antimicrob Agents       Date:  2008-10-02       Impact factor: 5.283

10.  Efficacy of rifampin and its combinations with imipenem, sulbactam, and colistin in experimental models of infection caused by imipenem-resistant Acinetobacter baumannii.

Authors:  María E Pachón-Ibáñez; Fernando Docobo-Pérez; Rafael López-Rojas; Juan Domínguez-Herrera; Manuel E Jiménez-Mejias; Andrés García-Curiel; Cristina Pichardo; Luis Jiménez; Jerónimo Pachón
Journal:  Antimicrob Agents Chemother       Date:  2010-01-04       Impact factor: 5.191

View more
  3 in total

1.  MTL genotypes, phenotypic switching, and susceptibility profiles of Candida parapsilosis species group compared to Lodderomyces elongisporus.

Authors:  Aylin Döğen; Banu Metin; Macit Ilkit; G Sybren de Hoog; Joseph Heitman
Journal:  PLoS One       Date:  2017-08-03       Impact factor: 3.240

2.  Isolation and characterization of antimicrobial compounds in plant extracts against multidrug-resistant Acinetobacter baumannii.

Authors:  Yoko Miyasaki; John D Rabenstein; Joshua Rhea; Marie-Laure Crouch; Ulla M Mocek; Patricia Emmett Kittell; Margie A Morgan; Wesley Stephen Nichols; M M Van Benschoten; William David Hardy; George Y Liu
Journal:  PLoS One       Date:  2013-04-22       Impact factor: 3.240

3.  Molecular characterization and antimicrobial susceptibility of Acinetobacter baumannii isolates obtained from two hospital outbreaks in Los Angeles County, California, USA.

Authors:  Wayne A Warner; Shan N Kuang; Rina Hernandez; Melissa C Chong; Peter J Ewing; Jen Fleischer; Jia Meng; Sheena Chu; Dawn Terashita; L'Tanya English; Wangxue Chen; H Howard Xu
Journal:  BMC Infect Dis       Date:  2016-05-04       Impact factor: 3.090

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.